1 study found for:    weill | Open Studies | "Epstein-Barr Virus Infections"
Show Display Options
Rank Status Study
1 Recruiting MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Conditions: Diffuse Large B-Cell Lymphoma;   Transformed Follicular Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma
Intervention: Drug: Alisertib (MLN8237) + Rituximab + Vincristine

Indicates status has not been verified in more than two years